@@ -224,7 +224,7 @@ export function Description() {
<p>To optimize AirBuddy for pulmonary delivery, we collaborated extensively with several experts, including <aonClick={()=>goToPagesAndOpenTab('weber','/human-practices')}>Prof. Weber, Dr. Große-Onnebrink</a> and <aonClick={()=>goToPagesAndOpenTab('tabid','/human-practices')}>Dr. Kolonko</a> as medical experts, <aonClick={()=>goToPagesAndOpenTab('kristian','/human-practices')}>Prof. Dr. Müller</a>, <aonClick={()=>goToPagesAndOpenTab('radukic','/human-practices')}>Dr. Radukic</a>, Benjamin Moorlach and the Physical and Biophysical Chemistry working group as academic experts form Bielefeld University and FH Bielefeld as well as <aonClick={()=>goToPagesAndOpenTab('corden','/human-practices')}>Corden Pharma</a> and <aonClick={()=>goToPagesAndOpenTab('rnhale','/human-practices')}>RNhale</a> as industrial experts. Throughout the <aonClick={()=>goToPagesAndOpenTab('delivery head','/engineering')}>development process</a>, we tested two commercially available kits: the <strong>Cayman Chemical LNP Exploration Kit (LNP-102)</strong> and the <strong>Corden Pharma LNP Starter Kit #2</strong>. While the Cayman kit demonstrated limited transfection efficiency, the Corden Pharma formulation significantly enhanced cellular uptake in lung tissues. Building on this, we integrated the <strong>SORT LNP</strong> method based on Wang's research [1], making our nanoparticles lung-specific. Additionally, we employed a <strong>spray-drying technique</strong> by RNhale [2] to improve the stability of our LNP, ensuring that it withstands the inhalation process without degradation and by that, <strong>AirBuddy</strong> was born. </p>
<p>The SORT LNPs are especially suited for pulmonary delivery due to their capacity for precise organ targeting. Their structural stability is maintained during the delivery process, and the spray-drying approach significantly enhances their resilience, allowing the LNPs to remain intact throughout inhalation. This stability is crucial for the efficient delivery of mRNA into lung epithelial cells, where PrimeGuide can effectively perform genome editing. To evaluate the delivery efficiency, we transfected HEK293 cells using fluorescent cargo and quantified the results through FACS analysis.</p>
<p>To ensure that AirBuddy meets the necessary standards for safety and efficacy, we conducted extensive <strong>characterization of the LNPs</strong> using techniques such as Zeta potential analysis, Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Cryogenic Electron Microscopy (cryo-EM). These methods confirmed the uniformity, stability, and optimal size distribution of the nanoparticles. Furthermore, <strong>cytotoxicity assessments</strong>, including MTT and proliferation assays, demonstrated that our LNPs are biocompatible and do not impede cell growth or function by the incorporation of <aonClick={()=>goToPagesAndOpenTab('it4','/engineering')}>PEG</a> and other ambivalent components. These findings reinforce AirBuddy's potential as a safe and effective tool for pulmonary delivery, with broad implications for gene therapies targeting lung diseases.</p>
<p>To ensure that AirBuddy meets the necessary standards for safety and efficacy, we conducted extensive <aonClick={()=>goToPageAndScroll ('In-Depth Characterization of LNPsH','/materials-methods')}>characterization of the LNPs</a> characterization of the LNPs using techniques such as Zeta potential analysis, Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Cryogenic Electron Microscopy (cryo-EM). These methods confirmed the uniformity, stability, and optimal size distribution of the nanoparticles. Furthermore, <strong>cytotoxicity assessments</strong>, including MTT and proliferation assays, demonstrated that our LNPs are biocompatible and do not impede cell growth or function by the incorporation of <aonClick={()=>goToPagesAndOpenTab('it4','/engineering')}>PEG</a> and other ambivalent components. These findings reinforce AirBuddy's potential as a safe and effective tool for pulmonary delivery, with broad implications for gene therapies targeting lung diseases.</p>